Skip Navigation

Cardiovascular Research 2005 67(4):655-666; doi:10.1016/j.cardiores.2005.04.016
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Anné, W.
Right arrow Articles by Heidbüchel, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anné, W.
Right arrow Articles by Heidbüchel, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation

Wim Annéa, Rik Willemsa, Tania Roskamsb, Paul Sergeantc, Paul Herijgersc, Patricia Holemansa, Hugo Ectora and Hein Heidbüchela,*

aDepartment of Cardiology, University Hospital Gasthuisberg, University of Leuven, Herestraat 49, B-3000 Leuven, Belgium
bDepartment of Pathology, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium
cDepartment of Cardiac Surgery, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium

* Corresponding author. Tel.: +32 16 34 42 48; fax: +32 16 34 42 40. Email address: Hein.Heidbuchel{at}uz.kuleuven.ac.be

Background: Atrial fibrillation (AF) is associated with extracellular matrix remodeling involving atrial fibrosis and atrial dilatation. Angiotensin II mediated pathways and matrix metalloproteinases (MMPs) have been implicated in these processes. Our aim was to study atrial structural remodeling and the expression of the angiotensin receptor subtypes and MMPs and their inhibitors (TIMPs) in patients with mitral valve disease with and without AF.

Methods and results: Biopsies from right and left atrial appendages (RA and LA) were taken from patients undergoing CABG (n = 9, all in sinus rhythm (SR)) or mitral valve surgery (MVS; n = 19; 9 with permanent AF and 10 in SR). Patients with MVS and AF had significantly larger atria (versus MVS and SR: p = 0.02; versus CABG: p<0.01). The MVS patients had significantly more fibrosis than the control CABG group. Fibrosis was increased in both the AF and SR MVS groups in the LA, but only in the MVS–AF group in the RA. These AF patients had significantly more tricuspid regurgitation than SR patients. MMP-1 was down-regulated in LA of MVS patients (p = 0.02) independent of the underlying rhythm (SR or AF; p = 0.95). In RA biopsies, MMP-1 was down-regulated only in the MVS and AF group. MMP-9 was down-regulated in the MVS patients compared to CABG both in the RA and LA, and without a difference between the SR and AF groups. Protein expression of AT-1, AT-2, MMP-2, TIMP-1, -2 and -4, TNF-{alpha}, and TNF-{alpha}-converting enzyme did not differ significantly between the 3 groups.

Conclusions: Concordant changes between MMP-expression and fibrosis during mitral valve disease, both in LA and RA, suggest involvement of MMPs in structural atrial remodeling. AF itself did not contribute to altered fibrosis or MMP-expression in the LA. The association between AF and RA changes may be precipitated by greater hemodynamic load due to tricuspid regurgitation in these patients.

KEYWORDS Arrhythmia; Valve disease; Fibrosis; Matrix metalloproteinases; Remodeling


Time for primary review 15 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur J EchocardiogrHome page
A. N. Borg, K. A. Pearce, S. G. Williams, and S. G. Ray
Left atrial function and deformation in chronic primary mitral regurgitation
Eur J Echocardiogr, June 16, 2009; (2009) jep085v1.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
Y. K. On, E.-S. Jeon, S. Y. Lee, D.-H. Shin, J.-O. Choi, J. Sung, J. S. Kim, K. Sung, and P. Park
Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure.
J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1515 - 1520.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
K. Kato, T. Fujimaki, T. Yoshida, M. Oguri, K. Yajima, T. Hibino, and T. Murohara
Impact of matrix metalloproteinase-2 levels on long-term outcome following pharmacological or electrical cardioversion in patients with atrial fibrillation
Europace, March 1, 2009; 11(3): 332 - 337.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
B. John, M. K. Stiles, P. Kuklik, S. T. Chandy, G. D. Young, L. Mackenzie, L. Szumowski, G. Joseph, J. Jose, S. G. Worthley, et al.
Electrical remodelling of the left and right atria due to rheumatic mitral stenosis
Eur. Heart J., September 2, 2008; 29(18): 2234 - 2243.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.